Medicilon, Dr. Lilly Appoints Xu as Chief Technology Officer

BOSTON , Dec. 20, 2024 /PRNewswire/ — Medicilon, a leading preclinical contract research organization (CRO), announced the release of Dr. Lilly appointed Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion and strengthen its capabilities to deliver cutting-edge R&D solutions.

Dr. holds a Ph.D. Xu. St Louis University’s Department of Biology is a recognized expert in pharmacokinetics, toxicology and drug metabolism. He has successfully led multiple global drug development programs from early discovery to clinical stages and has held leadership roles at major pharmaceutical and biotechnology companies including Pharmaron, Icagen, Purdue Pharma, Sanofi and Amgen.

Medicilon Founder and CEO Dr. “We are excited to welcome Dr. Xu at this important time in Medicilon’s growth,” said Chunlin Chen. “His extensive expertise and global perspective align with our vision to foster innovation and advance our international presence.”

Xu added, “I am honored to join Medicilon’s forward-thinking team. I look forward to contributing to platform innovation, accelerating the transition of research to clinical breakthroughs, and achieving milestones that will benefit our global customers and their patients.”

Medicilon continues to expand its advanced research platforms, including nucleic acids, ADCs, PROTACs, antibodies, and cell and gene therapies, strengthening its position as a leader in preclinical drug development.

Website:

Photograph –

View original content: